Today: 2 July 2026
Browse Category

Mergers & Acquisitions 4 November 2025 - 8 November 2025

Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer (PFE) Clinches $10 Billion Metsera Deal as Novo Nordisk Exits—What It Means for the Obesity Drug Race (Nov. 8, 2025)

Key takeaways Late Friday, Metsera accepted a sweetened offer from Pfizer: $65.60 per share in cash plus a contingent value right of up to $20.65 per share, valuing the biotech at up to $10 billion. On Saturday, Novo Nordisk said it would not increase its bid and exited the race, citing legal and regulatory risks tied to its two‑step proposal. Metsera’s board said Pfizer’s amended agreement carries lower antitrust risk and recommended shareholders approve it at a Nov. 13 meeting. PR Newswire+1
8 November 2025
···
Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer Inc. has secured a definitive agreement to acquire weight‑loss biotech Metsera in a transaction valued at up to $10 billion, ending a high‑stakes bidding war with Novo Nordisk and positioning Pfizer squarely back in the fast‑growing obesity market. Metsera accepted Pfizer’s revised offer late Friday; Novo said today it would not raise its competing bid. Reuters Pfizer’s final, sweetened bid prevailed after a week of public twists that included legal skirmishes and regulatory warnings. Metsera said the legal and regulatory risks tied to Novo’s proposal—flagged by the FTC—were “unacceptably high,” tipping the board toward Pfizer’s revised agreement. Novo responded that it would not increase its offer further, effectively bowing out. Reuters+1
8 November 2025
···
Metsera (NASDAQ: MTSR): Pfizer Clinches $10B Deal as Novo Nordisk Bows Out — What to Know Today (Nov. 8, 2025)

Metsera (NASDAQ: MTSR): Pfizer Clinches $10B Deal as Novo Nordisk Bows Out — What to Know Today (Nov. 8, 2025)

Pfizer sealed a deal to acquire Metsera for up to $10 billion, ending one of 2025’s fiercest pharma bidding wars and reshaping the obesity‑drug race. Below are the facts, context, and what’s next for MTSR shareholders and the GLP‑1 landscape. Pfizer won the contest for Metsera, agreeing to acquire the clinical‑stage obesity‑drug developer in a transaction valued at up to $10 billion. Metsera’s board cited legal and regulatory certainty in favoring Pfizer’s revised terms, while Novo Nordisk said it will not raise its competing proposal and is exiting the race. The merger is expected to close shortly after Metsera’s Nov. 13 special shareholder meeting, pending customary approvals. Reuters+1
8 November 2025
·····
Marvell Technology Stock Soars on AI Boom: Latest Price, Hot News & 2025 Outlook

Marvell Technology (MRVL) Slides as SoftBank Takeover Buzz Fades — Stock News for November 7, 2025

Summary: Marvell Technology traded lower on Friday after yesterday’s pop tied to reports that SoftBank explored a takeover earlier this year. Investors are now refocusing on fundamentals and the company’s next earnings catalyst in early December. MarketWatch+1 As of 19:27 UTC on November 7, 2025, MRVL changed hands at $88.64, down about 5% on the day. The session ranged between $85.12 and $94.16 after opening at $91.68. For context, Reuters lists a 52‑week range of $47.09–$127.48. Reuters
7 November 2025
··
Sweetgreen (NYSE: SG) Cuts 2025 Outlook, Sells Spyce Robotics to Wonder for $186.4M After Weak Q3 — 11/7/2025

Sweetgreen (NYSE: SG) Cuts 2025 Outlook, Sells Spyce Robotics to Wonder for $186.4M After Weak Q3 — 11/7/2025

Sweetgreen reported third‑quarter FY2025 revenue of $172.4 million, down 0.6% year over year. Same‑store sales fell 9.5%, driven by an 11.7% drop in traffic and product mix, partly offset by 2.2% of price increases. Digital remained a majority of sales, with 35.3% coming through owned digital channels. Restaurant‑level profit margin compressed to 13.1% from 20.1% a year ago, and adjusted EBITDA swung to ‑$4.4M from +$6.8M. The company opened six net new restaurants in the quarter. Business Wire Management cut full‑year guidance, now expecting $682–$688M in revenue, comps of ‑8.5% to ‑7.7%, restaurant‑level margins of 14.5%–15%, and adjusted EBITDA of ‑$13M to ‑$10M. Sweetgreen still plans 37 net new openings in 2025, 18 of which will feature Infinite Kitchen. Business Wire+1
7 November 2025
···
Archer Aviation (ACHR) Raises $650M, Moves to Buy Hawthorne Airport for $126M; Shares Slip After Q3 Update — Nov. 7, 2025

Archer Aviation (ACHR) Raises $650M, Moves to Buy Hawthorne Airport for $126M; Shares Slip After Q3 Update — Nov. 7, 2025

Archer Aviation Inc. unveiled a multi‑pronged update tied to its third‑quarter results: a $650 million equity raise, a deal to acquire control of Los Angeles’ Hawthorne Airport for $126 million, fresh flight‑test milestones for its Midnight eVTOL, and the closing of its Lilium patent portfolio purchase. The stock traded around $8.88 mid‑day as investors digested the capital raise and airport plan. Archer Aviation+1 HHR’s location—near LAX, SoFi Stadium, the Intuit Dome, The Forum, and Downtown LA—makes it a strategic hub for short‑hop urban missions Archer is targeting ahead of the LA28 Olympic Games. Industry coverage notes the airport is slated to be the central node of Archer’s LA network and a staging area for 2028 operations, subject to approvals. Archer Aviation+2flightglobal.com+2
7 November 2025
···
Brighthouse Financial (BHF) to Be Acquired by Aquarian Capital for $4.1B at $70/Share; Stock Jumps — Nov. 6, 2025

Brighthouse Financial (BHF) to Be Acquired by Aquarian Capital for $4.1B at $70/Share; Stock Jumps — Nov. 6, 2025

Brighthouse Financial, Inc. said this morning it has entered into a definitive agreement to be acquired by Aquarian Capital in an all‑cash deal valuing the company at approximately $4.1 billion, or $70.00 per share. The transaction would take the U.S. life insurer and annuity provider private and is expected to close in 2026, pending shareholder and regulatory approvals. Business Wire Key takeaways
6 November 2025
··
Strive Asset Management (ASST) prices upsized 12% preferred stock IPO to raise ~$160M; fresh Semler (SMLR) merger filing lands — Nov. 6, 2025

Strive Asset Management (ASST) prices upsized 12% preferred stock IPO to raise ~$160M; fresh Semler (SMLR) merger filing lands — Nov. 6, 2025

Strive, Inc.—the parent of Strive Asset Management, LLC—priced an upsized initial public offering of its Variable Rate Series A Perpetual Preferred Stock at $80 per share, expanding the deal to 2,000,000 shares for ~$160 million in expected gross proceeds. Settlement is slated for Monday, November 10, 2025, pending customary closing conditions. The preferred carries an initial 12% annual dividend, paid monthly beginning December 15, 2025, with a $100 stated amount and a framework that allows Strive to adjust the rate within defined limits. Barclays and Cantor are joint bookrunners, with Clear Street as co‑manager. Proceeds may fund Bitcoin purchases, income‑generating assets, share repurchases, debt reduction, and M&A. GlobeNewswire Separately, Semler Scientific filed a same‑day Form 8‑K providing supplemental disclosures about Strive in connection with the pending all‑stock merger, confirming recent capital actions and Bitcoin treasury details heading into the shareholder process. SEC+1
6 November 2025
···
Comstock Resources (CRK) Jumps as Q3 Results, $430M Divestiture and Rising RS Rating Put Haynesville Gas in Focus — Nov. 6, 2025

Comstock Resources (CRK) Jumps as Q3 Results, $430M Divestiture and Rising RS Rating Put Haynesville Gas in Focus — Nov. 6, 2025

FRISCO, Texas — Nov. 6, 2025. Shares of Comstock Resources, Inc. traded higher today after a week packed with catalysts: stronger third‑quarter results, progress on a $430 million asset sale, and a fresh technical tailwind as the stock’s Relative Strength rating ticked up. Midday, CRK changed hands around $21.14, up roughly 5.5%, within a 52‑week range of $11.41–$31.17. Reuters Technical momentum: Investor’s Business Daily highlighted CRK’s RS Rating rising to 85, a level technicians often view as signaling mounting relative strength. While IBD notes CRK isn’t at a formal “buy” point, the upgrade adds fuel to a rally that has built in recent sessions. Investors
6 November 2025
···
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) today: Court denies bid to block Novo–Metsera deal; Pfizer preps sweeter offer and leans on higher 2025 EPS outlook

Key takeaways 1) Court clears the way for Metsera to pivot to Novo’s richer bid.On Wednesday evening, the Delaware Chancery Court denied Pfizer’s TRO request that sought to keep Metsera bound to its earlier merger agreement with Pfizer. In a same‑day statement, Pfizer argued the decision “does not address the merits” and vowed to pursue its claims in parallel antitrust litigation. BioSpace’s Thursday write‑up and the company’s press release confirm the ruling and Pfizer’s plan to keep fighting. BioSpace+1
6 November 2025
····
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Google (GOOGL) Stock Today: Alphabet Rises on Apple–Siri AI Tie‑Up, Epic Play Store Settlement, and DOJ Nod for $32B Wiz Deal — Nov. 5, 2025

Updated Nov. 5, 2025. This article rounds up the major, same‑day developments affecting Alphabet/Google stock. At a glance: Alphabet traded roughly 2% higher intraday as three catalysts landed on the same day: reports that Apple will use Google’s Gemini AI model to power a revamped Siri, a proposed settlement with Epic Games that reshapes Android app‑store rules, and word that Google’s $32 billion acquisition of cloud‑security firm Wiz cleared U.S. DOJ antitrust review. Reuters+3Reuters+3Reuters+3
5 November 2025
···
Cheer Holding (CHR) Stock Skyrockets on Buyout Bids – Inside the AI Innovator’s Rollercoaster Ride

Cheer Holding (CHR) Stock Skyrockets on Buyout Bids – Inside the AI Innovator’s Rollercoaster Ride

Cheer Holding, Inc. is a China-based provider of advanced mobile internet infrastructure and digital content platforms. Through its subsidiaries, Cheer offers advertising and content production services in the Chinese market. The company has built a suite of consumer apps and services under the “CHEERS” brand, aiming to create an integrated digital ecosystem. Its flagship offerings include CHEERS Video, CHEERS e-Mall, and CHEERS App which combines professionally-produced content with shopping features. In recent years, Cheer Holding has pivoted heavily into emerging tech and AI-driven products. It operates CHEERS Telepathy, an AI content creation platform, and has rolled out apps like CheerChat, CheerReal, CheerCar, and even CHEERS Metaverse experiences. This broad portfolio blurs the line between online and offline, virtual and reality – the company’s vision is to integrate 5G, AR/VR, blockchain, and AI into a cohesive Web3.0 environment.
5 November 2025
··
Dow Dips as Fed Fears Slam Tech Stocks – Hot Economic Data Rattles Wall Street (Sept 25, 2025)

Regional Banks Roar Back? Q3 Surprises, Mega‑Mergers—and the One Risk Still Haunting 2025

Key facts: After two straight Fed cuts took the policy range down again in late October, the October Senior Loan Officer Opinion Survey painted a nuanced picture: tighter C&I standards on balance, but basically unchanged CRE standards and stronger demand for mortgages and HELOCs. In other words, lending isn’t shutting down, but banks are still protective—especially on business credit. Federal Reserve
5 November 2025
·········
Metsera (MTSR) Stock Soars 20% Amid $10B Bidding War – Pfizer vs Novo Nordisk Face Off

Metsera (MTSR) Stock Soars 20% Amid $10B Bidding War – Pfizer vs Novo Nordisk Face Off

Metsera’s stock has been on a meteoric rise in recent weeks, capped by a 20% jump on November 4, 2025 alonereuters.comreuters.com. The share price is now hovering in the low $70sreuters.com, a remarkable increase from just around $30–$33 in mid-September before any takeover talks emergedprnewswire.com. In fact, over the past 52 weeks the stock ranged from a low of about $12.30 to a new high of $73.60 set on November 4reuters.com – reflecting hundreds of percent in gains for early investors. This latest surge was directly tied to major news: both Pfizer and Novo Nordisk submitted sweetened acquisition offers for Metsera on November 4, escalating their bidding warreuters.comreuters.com. Upon word that Metsera’s board favored Novo’s higher bid – and that a Delaware judge would allow the bidding contest to proceed freely, rather than blocking it at Pfizer’s request – traders piled into the stock, driving it up over 20% intradayreuters.comreuters.com. By the close, Metsera was up roughly +$12.5 on the day, around $73 per sharereuters.com, as the market began pricing in the possibility of an ~$86/share takeover by Novo or a counteroffer near that range.
4 November 2025
···
Axcelis (ACLS) Stock Jumps on Q3 Earnings Beat and Veeco Merger: Key Insights & Outlook

Axcelis (ACLS) Stock Jumps on Q3 Earnings Beat and Veeco Merger: Key Insights & Outlook

Axcelis stock traded in the mid-$80s in early November 2025, rallying on earnings news. It closed around $86.24 on Nov 4, 2025, up about 5% for the day and roughly 8–9% over the two sessions surrounding its earnings report. This rebound comes after a soft October where ACLS had slid ~14% over a monthnasdaq.com, underperforming the tech sector. Even after the post-earnings pop, shares remain well below their 52-week high of ~$103 and about double the 52-week low near $40marketbeat.com, reflecting both the stock’s volatility and longer-term growth. Overall, year-to-date 2025 returns are around +17–22% for ACLSmarketscreener.com, outpacing many broader market benchmarks despite recent weakness. However, on a one-year basis the stock is down roughly 20%sahmcapital.com, as it gave back some of 2023’s huge gains. Long-term investors have still seen impressive growth – Axcelis stock is up ~235% over five yearssahmcapital.com – thanks to the company’s niche strength and previous semiconductor up-cycle. The stock’s beta is about 1.75marketbeat.com, indicating higher volatility than the market. Notably, institutional ownership is very highmarketbeat.com, signaling strong interest from funds and potentially contributing to volatility as sentiment shifts.
4 November 2025
····
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

The fight for Metsera is driven by fierce competition in GLP-1 obesity drugs. Novo Nordisk is the maker of Wegovy/Ozempic, and Eli Lilly’s drugs recently overtook Wegovy in US market sharereuters.com. Novo’s new CEO Mike Doustdar and the company’s controlling foundation have pushed for bolder moves after days of sliding market performancereuters.comreuters.com. In late October, Novo – which had already agreed a separate $5 billion deal to buy diabetes biotech Akero – suddenly “launched a bid…valuing [Metsera] at some $9 billion and crashing Pfizer’s deal”reuters.com. This was weeks after Novo’s top shareholder overhauled its board to demand a faster turnaround in the weight-loss arenareuters.comreuters.com. Pfizer, by contrast, has no obesity blockbuster drug of its own. In September it agreed to buy Metsera for up to $7.3 billion in order to jumpstart a presence in the roughly $150 billion obesity marketreuters.com. Its long-awaited annual results showed strong profits and a bumped-up full-year forecast, driven by cost cuts and steady core salesreuters.comreuters.com. But Pfizer immediately lost any lead when Novo swooped in.
4 November 2025
···
Kenvue (NYSE: KVUE) Stock Surges on $40B Buyout – Spin‑Off Saga, Tylenol Turmoil & Investor Outlook

Kenvue (NYSE: KVUE) Stock Surges on $40B Buyout – Spin‑Off Saga, Tylenol Turmoil & Investor Outlook

Kenvue Inc. is a leading consumer health company formed from Johnson & Johnson’s storied consumer products division. The name “Kenvue” combines “ken” and “vue”, reflecting a vision of insight-driven careen.wikipedia.org. As a spin-off, Kenvue took over J&J’s well-known retail brands, ranging from over-the-counter medicines to skincare and baby care. Today its portfolio spans three segmentsinvesting.com: Formally incorporated in 2022, Kenvue began trading on the NYSE in May 2023 after a highly anticipated IPOen.wikipedia.org. The IPO raised $3.8 billion – the largest U.S. listing in nearly two years – and initially valued Kenvue around $41 billionen.wikipedia.org. Johnson & Johnson retained a ~90% stake initially, but by July 2023 J&J had fully divested via a share exchange, making Kenvue a fully independent companyen.wikipedia.org. The new company immediately landed in the S&P 500 and even the S&P 500 Dividend Aristocrats indexen.wikipedia.org.
4 November 2025
···
Evoke Pharma (EVOK) Stock Skyrockets on Buyout News – What’s Behind the Surge?

Evoke Pharma (EVOK) Stock Skyrockets on Buyout News – What’s Behind the Surge?

Year-to-date chart of Evoke Pharma stock through early November 2025. Shares were volatile throughout 2025, and the Q4 acquisition announcement triggered a dramatic spike to new highs, bringing the stock roughly back to breakeven for the yeartipranks.com. Evoke Pharma’s stock has experienced extreme volatility in recent weeks. After trading in the mid-$4 to $5 range through October, EVOK plunged 10.9% on November 3, 2025 to $4.59 at the closetipranks.com. The very next day, news of the buyout sent the stock exploding upward – EVOK opened around $10.70 on Nov 4 and closed at $10.77, up roughly +134% in one sessiontipranks.com. In pre-market trading that morning, shares had been up as much as +133%tipranks.com, signaling the market’s immediate recognition of the lucrative $11/share acquisition price. Volume on Nov 4 exceeded 2.1 million shares, an enormous surge compared to EVOK’s ~29,000 three-month average daily volumetipranks.com. This indicates many traders rushed in upon the news.
4 November 2025
··
1 … 14 15 16 17 18 … 20

Stock Market Today

  • COMP Options See Heavy Action as Implied Volatility Spikes
    July 2, 2026, 2:05 PM EDT. Compass Inc (COMP) options drew attention today with the July 17, 2026 $2 call posting some of the highest implied volatility in the market. This signals traders are pricing in bigger price swings for the stock. Even so, analysts are holding back-COMP has a Zacks Rank #3 (Hold), and earnings consensus for the quarter fell from 21 cents to 9 cents per share in the last 60 days. The split between cautious analysts and active options traders suggests some are leaning into volatility to collect premium, betting the stock won't move as much as the options market is showing.
Go toTop